HC Wainwright reaffirmed their buy rating on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report released on Monday morning, Zacks.com reports.
Several other analysts have also recently weighed in on the company. ValuEngine raised Arcadia Biosciences from a sell rating to a hold rating in a report on Thursday, August 1st. National Securities reissued a buy rating and set a $15.00 price objective on shares of Arcadia Biosciences in a report on Thursday, May 9th.
Shares of NASDAQ:RKDA opened at $8.14 on Monday. The stock has a market capitalization of $38.17 million, a P/E ratio of -1.52 and a beta of -2.01. Arcadia Biosciences has a 1-year low of $1.82 and a 1-year high of $10.40. The company has a current ratio of 6.26, a quick ratio of 6.19 and a debt-to-equity ratio of 2.80. The business has a 50-day moving average price of $3.20 and a two-hundred day moving average price of $5.03.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Featured Article: What Are Cryptocurrencies?
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.